Last Updated: 19 Sep 2024
Executive Summary
Viking Therapeutics Inc. (VKTX) is a clinical-stage biopharmaceutical company focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California. VKTX has a market capitalization of $7.43 billion and the latest stock price is $64.45. The company has a strong balance sheet with $8.31 in book value per share. VKTX is not yet profitable, but analysts expect the company to become profitable in the future. The company has a strong pipeline of drugs in development, and analysts believe that VKTX has the potential to be a major player in the metabolic and endocrine disorders market.
Company Overview
Viking Therapeutics Inc. was founded in 2009. The company's mission is to develop and commercialize innovative therapies for patients with metabolic and endocrine disorders. VKTX has a team of experienced scientists and executives who are committed to developing new therapies that can improve the lives of patients.
VKTX's pipeline of drugs in development includes VK2001, a potential treatment for non-alcoholic steatohepatitis (NASH), and VK5211, a potential treatment for type 2 diabetes. VK2001 is currently in Phase 2 clinical trials, and VK5211 is currently in Phase 1 clinical trials.
Fundamental Analysis
VKTX is not yet profitable, but analysts expect the company to become profitable in the future. The company has a strong balance sheet with $8.31 in book value per share. VKTX has a strong pipeline of drugs in development, and analysts believe that VKTX has the potential to be a major player in the metabolic and endocrine disorders market.
Technical Analysis
VKTX's stock price has been in a downtrend since early 2023. The stock price has fallen from a high of $99.41 in January 2023 to a low of $8.28 in June 2023. The stock price is currently trading at $64.45.
The technical analysis of VKTX's stock price suggests that the stock is in a downtrend. The stock price is below its 50-day and 200-day moving averages. The stock price is also below its 52-week high.
Short Term Outlook
The short-term outlook for VKTX's stock price is negative. The stock price is in a downtrend, and there are no signs of a reversal. The stock price is likely to continue to fall in the short term.
Long Term Outlook
The long-term outlook for VKTX's stock price is positive. The company has a strong pipeline of drugs in development, and analysts believe that VKTX has the potential to be a major player in the metabolic and endocrine disorders market. The stock price is likely to rise in the long term.
Analyst Recommendations
Analysts have a strong buy rating on VKTX's stock. The average analyst target price is $113.55.
